Paeds Cases · paediatric-dermatology
A child recovering from carbamazepine-induced SJS-TEN overlap — long case
Long-case and structured-discussion OSCE on a 9-year-old girl recovering from carbamazepine-induced Stevens-Johnson syndrome-toxic epidermal necrolysis overlap: the acute recognition and immediate drug withdrawal, SCORTEN severity scoring and burn-unit disposition, the supportive-care-centred management with early ophthalmology, the no-proven-benefit position on immunomodulation, the ocular and skin long-term sequelae, lifelong carbamazepine and cross-reactive anticonvulsant avoidance, MedicAlert identification, and HLA-B*15:02 screening of at-risk relatives.
On this page & tools
Target exams
Candidate instructions (10-minute long-case discussion)
You are the paediatric registrar on the ward. A 9-year-old girl was admitted three weeks ago with Stevens-Johnson syndrome-toxic epidermal necrolysis overlap, six weeks after starting carbamazepine for new-onset focal epilepsy. She presented with fever, painful red eyes, crusted bleeding lips, dusky target lesions and sheet-like detachment of about 12 percent of body surface area. She is now recovering — her skin is re-epithelialising and her oral intake is improving, but she still has ocular discomfort and photophobia. The examiner asks you to discuss her acute management, the severity assessment, the long-term sequelae and follow-up, and the family pharmacogenetic and drug-avoidance plan. [1]
Your tasks are: [1]
- Outline the immediate acute management she should have received, including the single most important action. [10]
- Explain the SCORTEN severity assessment and how it informed her disposition. [1]
- Discuss the long-term sequelae she is at risk of and the follow-up she needs. [7]
- Outline her lifelong drug-avoidance plan and the family HLA pharmacogenetic screening. [4]
You are not expected to manage her ongoing ophthalmology care independently — the ophthalmology team is involved, but you should explain its importance. [10]
You have read the opening of this case. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship atlas.
References6Show ledgerHide ledger
- [1]Bastuji-Garin S; Fouchard N; Bertocchi M; Roujeau JC; et al SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol, 2000.PMID 10951229
- [3]Lonjou C; Borot N; Sekula P; Ledger N; et al A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics, 2008.PMID 18192896
- [4]Chung WH; Hung SI; Hong HS; Hsih MS; et al Medical genetics: a marker for Stevens-Johnson syndrome. Nature, 2004.PMID 15057820
- [7]Iriarte C; Karim SA; Nassim JS; Grenier PO; et al Infantile Stevens Johnson syndrome and toxic epidermal necrolysis: A systematic review of clinical features and outcomes in children ages 12 months and under. Pediatr Dermatol, 2022.PMID 35676891
- [9]Zimmermann S; Sekula P; Venhoff M; Motschall E; et al Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis. JAMA Dermatol, 2017.PMID 28329382
- [10]AlFada M; Alotaibi H; Alsharif S; Alani AH; et al Systematic review, methodological appraisal, and recommendation mapping of clinical practice guidelines for managing patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Dermatolog Treat, 2025.PMID 40010698